Rare surgery for recurrent cancer: how does it affect quality of life?
NCT ID NCT07594327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 21 patients who had a very extensive surgery called pelvic exenteration for recurrent gynecologic cancer. The goal is to understand how the surgery affects their quality of life and sexuality using standard questionnaires. The results will help doctors better prepare and support future patients considering this option.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better select and counsel patients for pelvic exenteration, improving post-surgery quality of life.
- What could go wrong
- This is a small, observational study with only 21 participants, so findings may not apply to all patients. It does not test a new treatment or intervention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 21 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who underwent pelvic exenteration for gynecologic cancer at Tampere University Hospital on or after January 1, 2000
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patient age over 18 years * a diagnosis of gynecologic cancer * having undergone exenteration surgery on or after January 1, 2000 (at least 6 months prior) * the ability to read and write Finnish Exclusion Criteria: * cognitive and/or neurological disease that affects physical functioning and may therefore influence sexual functioning or make it difficult to respond to the questionnaire
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tampere University Hospital
Tampere, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Triple oral drug combo targets two stubborn gynecologic cancers
- Shorter, personalized radiation may target endometrial cancer with fewer side effects
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
- Your gut bacteria may hold the key to whether immunotherapy works